Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2017/7481597 http://scihub22266oqcxt.onion/10.1155/2017/7481597 C5331476!5331476!28293638     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Res+Int 2017 ; 2017 (ä): ä Nephropedia Template TP {{tp|p=28293638|t=2017. Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors |pdf=|usr=}}{{28293638}} gab.com Text Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=28293638 #FOAvip Protease inhibitor (PI) may cause abnormal glucose metabolism, abnormal lipid metabolism, and metabolic syndrome in HIV-infected adults but less well studied in Asian adolescents. This cross-sectional study evaluated anthropometric factors, oral glucose tolerance test, and lipid profiles of perinatally HIV-infected Thai adolescents who had received PI-based antiretroviral therapy for at least 6 months. Eighty adolescents were enrolled [median (IQR) age 16.7 (14.6?18.0) years, 42 males]. Metabolic syndrome, prediabetes, and type 2 diabetes mellitus (T2DM) were found in 8 (10%), 17 (22.1%), and 3 (3.8%) adolescents, respectively. Dyslipidemia was found in 56 (70%) adolescents, with hypertriglyceridemia being the most common type. In multivariate analysis, presence of lipohypertrophy (OR: 25.7, 95% CI: 3.2?202.8; p = 0.002) and longer duration of PI use (OR: 1.04, 95% CI: 1.00?1.08; p = 0.023) were associated with metabolic syndrome. Obesity (OR: 7.71, 95% CI: 1.36?43.7; p = 0.021), presence of lipohypertrophy (OR: 62.9, 95% CI: 4.97?795.6; p = 0.001), and exposure to stavudine for ?6 months (OR: 8.18, 95% CI: 1.37?48.7; p = 0.021) were associated with prediabetes/T2DM, while exposure to tenofovir for ?6 months reduced the risk (OR: 0.17, 95% CI: 0.04?0.78; p = 0.022). Metabolic disorders were commonly found in adolescents receiving PI. Careful monitoring and early intervention to modify cardiovascular risk should be systematically implemented in this population particularly those with exposure to stavudine. Twit Text FOAVip Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=28293638 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28293638 #FOAvip English Wikipedia <ref>{{Cite pmid|28293638}}</ref> Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors #MMPMID28293638 Santiprabhob J; Tanchaweng S; Maturapat S; Maleesatharn A; Lermankul W; Sricharoenchai S; Wittawatmongkol O; Lapphra K; Phongsamart W; Chokephaibulkit K Biomed Res Int 2017[]; 2017 (ä): ä PMID28293638show ga Protease inhibitor (PI) may cause abnormal glucose metabolism, abnormal lipid metabolism, and metabolic syndrome in HIV-infected adults but less well studied in Asian adolescents. This cross-sectional study evaluated anthropometric factors, oral glucose tolerance test, and lipid profiles of perinatally HIV-infected Thai adolescents who had received PI-based antiretroviral therapy for at least 6 months. Eighty adolescents were enrolled [median (IQR) age 16.7 (14.6?18.0) years, 42 males]. Metabolic syndrome, prediabetes, and type 2 diabetes mellitus (T2DM) were found in 8 (10%), 17 (22.1%), and 3 (3.8%) adolescents, respectively. Dyslipidemia was found in 56 (70%) adolescents, with hypertriglyceridemia being the most common type. In multivariate analysis, presence of lipohypertrophy (OR: 25.7, 95% CI: 3.2?202.8; p = 0.002) and longer duration of PI use (OR: 1.04, 95% CI: 1.00?1.08; p = 0.023) were associated with metabolic syndrome. Obesity (OR: 7.71, 95% CI: 1.36?43.7; p = 0.021), presence of lipohypertrophy (OR: 62.9, 95% CI: 4.97?795.6; p = 0.001), and exposure to stavudine for ?6 months (OR: 8.18, 95% CI: 1.37?48.7; p = 0.021) were associated with prediabetes/T2DM, while exposure to tenofovir for ?6 months reduced the risk (OR: 0.17, 95% CI: 0.04?0.78; p = 0.022). Metabolic disorders were commonly found in adolescents receiving PI. Careful monitoring and early intervention to modify cardiovascular risk should be systematically implemented in this population particularly those with exposure to stavudine. äMetabolic Disorders in HIV-Infected Adolescents Receiving Protease Inh(epmc).pdf DeepDyve Pubget Overpricing